| pubmed-article:12095076 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12095076 | lifeskim:mentions | umls-concept:C0009079 | lld:lifeskim |
| pubmed-article:12095076 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:12095076 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:12095076 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:12095076 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:12095076 | pubmed:dateCreated | 2002-7-3 | lld:pubmed |
| pubmed-article:12095076 | pubmed:abstractText | A retrospective cohort study, with a mirror-image design, was used to measure inpatient service utilization in 63 consecutive patients started on clozapine from a geographical catchment area compared to a control group matched for previous inpatient service use. An intent-to-treat analysis, including those patients (n = 28) who discontinued clozapine during the study period, showed a significant reduction in number of admissions and total time spent in hospital in the 2 years following clozapine initiation compared to the previous 2 years and to the follow-up period in the control group. This translated into a reduction of 7,300 pounds in hospitalization costs per patient started on clozapine, over the 2-year period. In those patients who continued clozapine treatment for the whole of the 2-year period, there was a two-thirds reduction in number of admissions and total time spent in hospital compared to no change in the clozapine discontinuers. These findings suggest that clozapine is a clinically and cost-effective intervention for severe schizophrenia in routine clinical settings. | lld:pubmed |
| pubmed-article:12095076 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12095076 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12095076 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12095076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12095076 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12095076 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12095076 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:12095076 | pubmed:issn | 0269-8811 | lld:pubmed |
| pubmed-article:12095076 | pubmed:author | pubmed-author:BrownPP | lld:pubmed |
| pubmed-article:12095076 | pubmed:author | pubmed-author:LewisS WSW | lld:pubmed |
| pubmed-article:12095076 | pubmed:author | pubmed-author:HayhurstK PKP | lld:pubmed |
| pubmed-article:12095076 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12095076 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:12095076 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12095076 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12095076 | pubmed:pagination | 169-75 | lld:pubmed |
| pubmed-article:12095076 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:meshHeading | pubmed-meshheading:12095076... | lld:pubmed |
| pubmed-article:12095076 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12095076 | pubmed:articleTitle | The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. | lld:pubmed |
| pubmed-article:12095076 | pubmed:affiliation | School of Psychiatry and Behavioural Sciences, University of Manchester, Wythenshawe Hospital, UK. khayhurst@fs1.with.man.ac.uk | lld:pubmed |
| pubmed-article:12095076 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12095076 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12095076 | lld:pubmed |
